Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company focused on developing therapeutic candidates. Its business centers on drug research, clinical development, and the advancement of proprietary pharmaceutical assets.

5.14

5.14

— Telomir Pharmaceuticals, Inc.
%
Drug Development Programs100% Discovery and development of proprietary pharmaceutical candidates.

Telomir does not appear to sell commercial products yet; its primary counterparties are investors, research partners,...

  • Capital providersprimary

    Investors and financing counterparties support the company while it advances its pipeline.

  • Research and clinical partnerssecondary

    Contract research and development collaborators help generate data and progress candidates.

  • Future commercial partnerssecondary

    Potential licensees or pharma partners may acquire rights to assets if development succeeds.

Telomir Pharmaceuticals is headquartered in the United States and operates as a U.S.-based development-stage...

  • •Headquartered in the United States
  • •No disclosed country-level revenue in the provided filings
  • •Operations are centered on pharmaceutical development activities
  • •Geographic exposure is mainly tied to U.S. capital markets and research activity

The company’s strategy is to advance its pharmaceutical pipeline through research, development, and regulatory...

01
Advance pipeline assetsmedium-term

Clinical and preclinical progress is the main driver of value in a development-stage pharma company.

02
Secure development fundingshort-term

R&D programs require ongoing capital before any product revenue can be generated.

03
Protect intellectual propertylong-term

Patent and know-how protection can support future partnering and exclusivity.

As a pharmaceutical development company, Telomir faces the usual risks of clinical failure, regulatory delay, and...

critical

Clinical development failure

Drug candidates can fail in preclinical or clinical testing, eliminating expected value from the pipeline.

Scope
Pipeline assets
Materiality
high
high

Regulatory approval risk

Pharmaceutical products require extensive regulatory review before commercialization.

Scope
Development programs
Materiality
high
high

Financing and dilution risk

Development-stage companies often rely on external capital to fund R&D and operations.

Scope
Corporate funding
Materiality
high
medium

Intellectual property risk

Patent challenges or weak protection can reduce exclusivity and partnering value.

Scope
Pipeline and licensing value
Materiality
medium
Research and development expense
Core operating expense
Fair value of equity instruments
Non-cash gains or losses
Intangible asset impairment
Balance sheet and earnings
Revenue recognition for collaborations
Future revenue timing

MIRA PHARMACEUTICALS, INC.

MIRA · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Semnur Pharmaceuticals, Inc.

SMNR · Pharmaceutical Preparations

Olema Pharmaceuticals, Inc.

OLMA · Pharmaceutical Preparations

TENAX THERAPEUTICS, INC.

TENX · Pharmaceutical Preparations

Tectonic Therapeutic, Inc.

TECX · Biological Products, (No Diagnostic Substances)

: 29/04/2026